SEC Form 4 · accession 0001104659-18-030636
Nabriva Therapeutics plc · NBRV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Charles A Rowland Jr.
Director
Period of report
May 2, 2018
Accepted (ET)
May 4, 2018 · 4:06 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001641640
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1,F2 | — | May 2, 2018 | A | 29,000 | A | — | May 2, 2028 | Ordinary Shares | 29,000 | 29,000 | D |
Explanation of responses
- F1The exercise price is $4.91 per share.
- F2This option was granted on May 2, 2018. Vesting began on May 2, 2018 and ends on May 2, 2019. One hundred percent (100%) of the option will vest on May 2, 2019.